Areas of Expertise

Photo of Catherine Wilson
Catherine’s areas of expertise include: EU and UK Regulatory Affairs for various types of CBD/cannabinoids and medicinal cannabis, food supplements and novel foods, residues of THC in foods/food supplements, CBD in cosmetics and market entry opportunities.  

Catherine was one of the early pioneers of the hemp cannabinoid industry and has experience in product formulations and an in-depth knowledge of purchasing behaviour including key reasons  consumers buy CBD products. She believes that there is enormous scope for developing  OTC medications. 

Catherine also has knowledge of the UK medical cannabis prescription market and a sound overview of all the various EU Countries varying policies and availability of prescribed medicinal cannabis. She held various roles within the European Industrial Hemp Association (EIHA). EIHA defends and represents the interest of the entire hemp value chain, from seed to shelf. She represented the industry with UK Regulatory Agencies (FSA, MHRA) for six years. She has also experience of working with the UK Health Safety Executive and the Department of Business, Enterprise and Regulatory Reform. In her various roles as Board Member, Vice President and now member of the Advisory committee of EIHA she contributed in developing key policy documents and attended meetings at the EU Commission in Brussels with PAFF and SCOPAFF.  

Catherine is also a member of the novel food working group whose responsibility was to submit the novel food application for CBD isolate, full spectrum and synthetic CBD to both EFSA and the UK FSA. She also contributed to developing the clinical trial protocol for the largest ever study on the effect of THC in humans. 

Catherine says: “‘I’m delighted to join Life Sciences Law as a Regulatory Affairs consultant and look forward to contributing my experience and expertise in the CBD and medicinal cannabis sector to enable executives to decipher notoriously complex legislation and regulations which will in-turn help them to make informed decisions.” 

Life Science Law’s Founder, Wendy Lloyd Goodwin, adds: “We are really excited to have Catherine on board. The cannabinoid market is changing, and Catherine’s expertise and informed insights in this area are second to none.”   

In the coming months, we will be publishing some of Catherine’s insights into relevant areas of interest in the industry.

For more information on the legal implications of launching cannabinoids into the medical market, contact us today. Our team of experts can partner with you throughout your journey.